NPS maintained at buy by Jefferies

NPS Pharmaceuticals, Inc. was kept at its buy rating by Jefferies & Co., Inc. analyst Adam Walsh on news that additional Preos trials are needed prior to approval. Significant near-term share price appreciation is unlikely, according to the analyst, given a lack of catalysts and balance sheet concerns. For the second quarter, NPS reported a non-GAAP loss per share of $0.85, compared to the analyst's loss per share estimate of $0.84. Shares of the Salt Lake City-based pharmaceutical company were down 18 cents, or 4.60%, at $3.73, on volume of 501,793 shares versus the three-month running average of 820,022 shares. (Nasdaq: NPSP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.